PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC 2012 October 1.
Published in final edited form as:
PMCID: PMC3178745
NIHMSID: NIHMS315451

Cutting Edge: Mouse CD300f (CLM-1) recognizes outer-membrane exposed phosphatidylserine and can promote phagocytosis

Abstract

Reportedly, CD300f negatively regulates interactions between dendritic and T cells, and acts as an anti-inflammatory molecule in a multiple sclerosis mouse model. We found that a CD300f/Fc chimeric protein specifically binds to apoptotic/dead splenocytes and to apoptotic cells from starved or irradiated lymphocytic cell lines; an observation extended to insect cells. CD300f also binds PMA/ionomycin-activated splenocytes and Ag-stimulated T cells, an interaction inhibited by Annexin V. By ELISA, co-sedimentation and surface plasmon resonance using phospholipid containing liposomes, we show that CD300f preferentially binds phosphatidylserine and requires a metal ion. Exogenous expression of CD300f in cell lines results in enhanced phagocytosis of apoptotic cells. We conclude that expression of CD300f conveys additional capacity to recognize phosphatidylserine to myeloid cells. The result of this recognition may vary with the overall qualitative and quantitative receptor content, as well as signaling capacity of the expressing effector cell, but enhanced phagocytosis is one measurable outcome.

Introduction

The human CD300 family of receptors are Type I transmembrane proteins that contain a single IgV-like extracellular domain. Four members of the family contain a charged residue in their transmembrane domain and associate with ITAM-containing adaptor molecules like DAP12 and FcεRIγ; two other members, CD300a and -f, contain extended cytoplasmic tails with tyrosine based signaling motifs, including ITIMs. Mouse CLM-1 appears to be the functional orthologue of CD300f, as they have in common consensus ITIM motifs and the ability to bind phosphatases (1, 2).

CD300 molecules are expressed on leukocytes and they can positively or negatively augment cellular responses, depending on the character of their signaling motifs (2). Most of this information has been obtained by Ab cross-linking, as essentially nothing is known about the ligands. Mouse CD300f was first described as an in vitro negative regulator of osteoclastogenesis (1). Its expression is largely confined to myeloid cells (1, 3, 4), where in vitro cross-linking studies indicate it can serve as an inhibitory or activating receptor (1, 5, 6) and can mediate caspase-independent cell death (7). Using CD300f deficient mice in a multiple sclerosis mouse model, it was shown that CD300f acts as a negative regulator of myeloid cell activity by suppressing demyelination, and the release of inflammatory cytokines (4). Blockade of CD300f recognition enhanced DC-initiated T-cell proliferation and antigen-specific T-cell responses both in vitro and in vivo (3) and indicated that T cells expressed a CD300f- specific ligand.

We show that a CD300f/Fc chimeric protein binds activated T lymphocytes, as well as apoptotic lymphocytes and insect cells, indicating evolutionary conservation of the ligand, and that the binding can be inhibited by Annexin V. Using a variety of approaches with phospholipid containing liposomes, we show that CD300f preferentially binds phosphatidylserine and that its expression can enhance phagocytosis.

Materials and Methods

Chimeric proteins

We created a chimeric protein with the extracellular part of mouse CD300f fused to human Fc (CD300f/Fc) (Supplemental Table I); hLAIR-1R65K/Fc (LAIR-1/Fc) was used as a negative control (8). They were purified from culture supernatants by protein A-Sepharose columns.

Binding assay

T cells (>98% pure) were isolated from spleens of C57BL/6 mice by negative selection (MACS MicroBeads, Miltenyi Biotec). After blocking Fc receptors, cells were stained with AlexaFluor488-conjugated chimeric proteins for 1 h at RT and analyzed by flow cytometry. For binding inhibition, the cells were incubated with 10 μg of Annexin V (BD) for 30 min before staining.

Flow cytometry

Abs used: CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7) and CD69 (H1.2F3), conjugated to FITC, PE, PE-Cy5.5, PE-Cy7 or APC. 7-AAD was used to detect dead cell populations. Data were collected on BD FACSort flow cytometer using Cell Quest and analyzed with FlowJo.

Preparation of phospholipid containing liposomes

Synthetic 1-palmitoyl-2-oleoyl (PO) phosphatidylserine (PS), (PO)phosphatidylglycerol (PG), 1, 2-dioleyol phosphatidylcholine (DOPC), and bovine liver L-α-phosphatidylinositol (PI) were from Avanti Polar Lipids. Liposomes were prepared by evaporating the chloroform from the desired phospholipid mixture with N2 gas. Large multi-lamellar vesicles were formed by swirling in 10 mM HEPES pH 7.4 with 140 mM NaCl. Small unilamellar vesicles were prepared by sonication for 10 min on ice with minute gap intervals. Large vesicles were removed by 45μ filters.

BIACORE analysis

1 mM liposomes were immobilized on L1 a sensor chip and blocked with BSA. CD300f/Fc was injected and its binding recorded. After dissociation of mCD300f with 2.5M NaCl + 5 mM EDTA, AnnexinV was passed through to block the binding; the unbound AnnexinV was removed with running buffer (10mM HEPES pH 7.4, 140mM NaCl and 2.5 mM CaCl2). CD300f/Fc protein was injected again and binding to the L1-PS sensor that was blocked by AnnexinV was recorded. Data were analyzed by BIACORE 3000 and BIAevaluation Software.

Sedimentation assay

The complex formed by liposomes and binding proteins localizes in the pellet fraction, whereas proteins not binding the liposomes remain in the supernatant fraction. The PS:PC (4:1), and PC:PS (4:1) liposomes (0.5 mM) were incubated with 25 μg/ml of CD300f/Fc protein for 45 min at RT and centrifuged at 100,000 × g for 1h. The pellet fractions and supernatant fractions (precipitated with 10% TCA) were re-suspended in loading buffer, resolved by SDS-PAGE and stained with Coomassie Blue.

ELISA

1 mM liposomes in HBS-buffered saline were incubated in 96-well maxisorp plates at 4°C overnight. The wells were blocked with 2% BSA for 2h at RT and incubated with CD300f/Fc (15 μg/ml) for 2h at RT. The plate was washed and incubated with anti-human Ig Ab coupled to HRP (Jackson ImmunoResearch) for 1h at RT before measuring absorbance at 450 nm.

Phagocytosis of apoptotic cells

Mouse fibroblast L929 cells were used for phagocytic assays (9). Cells were transfected with an empty vector (pcDNA3.1+) or vector encoding mouse CD300f (Supplemental Table I). Thymocytes isolated from C57BL/6 mice were incubated for 6 h at 37°C with 10μM dexamethasone (Sigma), labeled with TFL-4 (Oncoimmunin), washed and added to L929 cells cultured on glass dishes at a ratio of 5:1. After incubation, L929 cells were washed, treated with trypsin-EDTA, fixed and analyzed by flow cytometry. For microscopy, L929 cells were washed, fixed and visualized by Zeiss LSM710 laser-scanning confocal microscope. The images were obtained using 63X Plan-Apochromat objective and Zeiss ZEN software. To verify the engulfment of apoptotic cells by L929 cells images were obtained along the z-axis. A representative single optical section is shown in the figure. Animal study protocols were reviewed and approved by the NIAID Animal Care and Use Committee.

Results and Discussion

CD300f binds to apoptotic cells

We found that CD300f/Fc, but not LAIR-1/Fc, preferentially bound to splenocytes with low FSC and SSC (R1) (Fig. 1A), indicating that CD300f recognizes cells that are apoptotic or dead. Induction of cell death by starvation or gamma irradiation resulted in increased specific binding of CD300f/Fc to 7-AAD-positive R1.1 cells (Fig. 1B), as well as T and B cell lines (Supplemental Fig. 1A). The CD300f/Fc fusion protein also bound effectively to apoptotic insect SC2 cells (Supplemental Fig. 1B), demonstrating that the ligand for CD300f is conserved among evolutionary distant species.

Figure 1
Recombinant CD300f/Fc binds to dead cells

CD300f binding to the surface of activated cells is blocked by Annexin V

Although CD300f/Fc protein bound strongly to apoptotic/dying splenocytes, some binding of the chimeric protein to 7-AAD-negative cells was also observed (Fig. 1A), indicating that the ligand for CD300f can be expressed on the surface of live cells. CD300f/Fc bound specifically to OVA-activated (CD69+) CD4 and CD8 splenocytes from OVA-immunized mice and that there was virtually no interaction with the non-activated (CD69) population of T cells (Fig. 2A). A hallmark of cell death is the transfer of phospholipids, such as phosphatidylserine (PS) from the inner to the outer leaflet of the plasma membrane (10); however, the appearance of PS on the cell surface is not restricted to apoptosis and some cells (e.g. T and B cells) display PS on the cell surface in response to activation (11, 12). Since CD300f/Fc bound to apoptotic and activated T cells, as well as dead cells, we hypothesized that the phospholipid PS could be the ligand for CD300f. Therefore, we isolated splenic CD4 T cells, stimulated them with PMA/ionomycin and investigated the binding of CD300f/Fc to the cells treated or not with Annexin V, a protein known to specifically bind PS (13). Following PMA/ionomycin treatment, we analyzed both apoptotic (7-AAD+) and non-apoptotic (7-AAD) CD4 T cell populations (Fig. 2B). In agreement with previous results (Fig. 1), CD300f/Fc bound to a pool of apoptotic T cells. Importantly, the pretreatment of cells with Annexin V lead to a 2-fold decrease of CD300f binding (Fig. 2B). Stimulation with PMA/ionomycin resulted in activation of a portion of live T cells (7-AADCD69+) and subsequent binding of CD300f/Fc. Similarly to apoptotic cells, pretreatment of activated cells with Annexin V resulted in 50% inhibition of CD300f binding. The marginal binding of the CD300f/Fc to the 7-AAD CD69 CD4 T cell population was also blocked by Annexin V.

Figure 2
Binding of CD300f/Fc to activated T cells is inhibited by Annexin V

CD300f binds phosphatidylserine

The ability of Annexin V to block binding of CD300f/Fc to apoptotic or activated T cells (Fig. 2) suggested that PS is the ligand for CD300f. Since binding of Annexin V and other proteins to PS is dependent on Ca2+, we investigated whether CD300f binding to dead cells also required a metal ion. The presence of EDTA or EGTA chelating agents abolished the binding of CD300f/Fc to 7-AAD+ cells, indicating the requirement for metal ions, likely Ca2+ (Fig. 3A). We directly assessed the binding of CD300f to PS with liposomes containing different phospholipids by ELISA and surface plasmon resonance (SPR). While the LAIR-1/Fc did not bind any liposomes, CD300f fusion protein bound predominantly to liposomes containing PS and binding correlated with the level of PS present in the assay (Fig. 3B). Additionally, CD300f, but not LAIR-1/Fc, was found to associate with liposomes containing PS in a lipid sedimentation assay. Increasing the concentration of PS in the liposomes resulted in a larger amount of CD300f/Fc co-sedimenting with the liposomes (Fig. 3C). Finally, using SPR, we demonstrated that CD300f/Fc bound very efficiently to PS-containing liposomes. Importantly, after removal of CD300f/Fc bound to the PS and subsequent blocking of PS by Annexin V, the binding of CD300f/Fc was substantially reduced (Fig. 3D), further demonstrating that PS is a specific ligand of CD300f. We also found that Annexin V inhibited binding of CD300f/Fc to pure PS or dead cells in a dose-dependent manner (Supplemental Fig. 1C, D).

Figure 3
Binding of CD300f to phosphatidylserine (PS)

CD300f positively regulates phagocytosis of apoptotic cells

Since PS exposure on the cell surface can act as an “eat me” signal (14) and the clearance of dead cells is important for immune homeostasis (15), we investigated whether the presence of CD300f affects phagocytosis of apoptotic cells. We transfected mouse L929 cells with CD300f and analyzed the ability of the transfected cells to phagocytose apoptotic thymocytes. The cells expressing CD300f phagocytosed between 30–50% more apoptotic cells compared to control-transfected L929 cells (Fig. 4A, B). The presence of soluble CD300f/Fc, but not LAIR-1/Fc, interfered with uptake of the apoptotic cells by CD300f transfected cells (data not shown). Examination by confocal microscopy verified that phagocytosis and not adherence was occurring; moreover, contrary to the mock-transfected cells, CD300f transfected cells often contained several apoptotic cells (Fig. 4C). We obtained similar results with NIH3T3 cells expressing CD300f (not shown). These results show that recognition of apoptotic cells by CD300f can have a stimulatory role in aiding the clearance of apoptotic cells, in agreement with studies demonstrating that CD300f can provide activation signals (6, 7). In addition to its ITIM motifs, the cytoplasmic tail of mCD300f has an ITSM switch motif and two other tyrosines, one of which may be involved in PI3K binding (7). Accordingly, future studies will be directed toward elucidating the molecular basis for the observed enhanced phagocytosis.

Figure 4
Expression of CD300f enhances phagocytosis of apoptotic thymocytes

Supplementary Material

Abbreviations used in this article

PS
phosphatidylserine
PC
phosphatidlycholine
CLM-1
CMRF-like molecule-1
RT
room temperature
FSC
forward scatter
SSC
side scatter

Footnotes

The online version of this article contains supplemental material.

References

1. Chung DH, Humphrey MB, Nakamura MC, Ginzinger DG, Seaman WE, Daws MR. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. J Immunol. 2003;171:6541–6548. [PubMed]
2. Clark GJ, Ju X, Tate C, Hart DN. The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends Immunol. 2009;30:209–217. [PubMed]
3. Shi L, Luo K, Xia D, Chen T, Chen G, Jiang Y, Li N, Cao X. DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses. Blood. 2006;108:2678–2686. [PubMed]
4. Xi H, Katschke KJ, Jr, Helmy KY, Wark PA, Kljavin N, Clark H, Eastham-Anderson J, Shek T, Roose-Girma M, Ghilardi N, van Lookeren Campagne M. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. J Exp Med. 2010;207:7–16. [PMC free article] [PubMed]
5. Izawa K, Kitaura J, Yamanishi Y, Matsuoka T, Oki T, Shibata F, Kumagai H, Nakajima H, Maeda-Yamamoto M, Hauchins JP, Tybulewicz VL, Takai T, Kitamura T. Functional analysis of activating receptor LMIR4 as a counterpart of inhibitory receptor LMIR3. J Biol Chem. 2007;282:17997–18008. [PubMed]
6. Izawa K, Kitaura J, Yamanishi Y, Matsuoka T, Kaitani A, Sugiuchi M, Takahashi M, Maehara A, Enomoto Y, Oki T, Takai T, Kitamura T. An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells. J Immunol. 2009;183:925–936. [PubMed]
7. Can I, Tahara-Hanaoka S, Hitomi K, Nakano T, Nakahashi-Oda C, Kurita N, Honda S, Shibuya K, Shibuya A. Caspase-independent cell death by CD300LF (MAIR-V), an inhibitory immunoglobulin-like receptor on myeloid cells. J Immunol. 2008;180:207–213. [PubMed]
8. Tang X, Narayanan S, Peruzzi G, Apara A, Natarajan K, Margulies DH, Coligan JE, Borrego F. A single residue, arginine 65, is critical for the functional interaction of leukocyte-associated inhibitory receptor-1 with collagens. J Immunol. 2009;182:5446–5452. [PMC free article] [PubMed]
9. Park SY, Jung MY, Kim HJ, Lee SJ, Kim SY, Lee BH, Kwon TH, Park RW, Kim IS. Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ. 2008;15:192–201. [PubMed]
10. Leventis PA, Grinstein S. The distribution and function of phosphatidylserine in cellular membranes. Annu Rev Biophys. 2010;39:407–427. [PubMed]
11. Elliott JI, Sardini A, Cooper JC, Alexander DR, Davanture S, Chimini G, Higgins CF. Phosphatidylserine exposure in B lymphocytes: a role for lipid packing. Blood. 2006;108:1611–1617. [PubMed]
12. Fischer K, Voelkl S, Berger J, Andreesen R, Pomorski T, Mackensen A. Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood. 2006;108:4094–4101. [PubMed]
13. Creutz CE. The annexins and exocytosis. Science. 1992;258:924–931. [PubMed]
14. Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med. 2010;207:1807–1817. [PMC free article] [PubMed]
15. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol. 2010;6:280–289. [PubMed]